ヨウ化イソプロパミド
プリアミド · γ-(アミノカルボニル)-N-メチル-N,N-ジイソプロピル-γ-フェニルベンゼン-1-プロパンアミニウム·ヨージド · N-(3-カルバモイル-3,3-ジフェニルプロピル)-N,N-ジイソプロピルメタンアミニウム·ヨージド · ジプラミド · よう化イソプロパミド · チリミド · イソプロパマイド · サヌルシン
識別子と物理属性
| CAS No. | 71-81-8 |
|---|---|
| 分子式 | C23H33IN2O |
| 平均分子量 | 480.4 g/mol |
| 単同位体質量 | 480.16376 g/mol |
| SMILES | CC(C)[N+](C)(CCC(C(N)=O)(c1ccccc1)c1ccccc1)C(C)C.[I-] |
| InChIKey | BFSMWENDZZIWPW-UHFFFAOYSA-N |
| PubChem CID | 6284 |
| ChEMBL | CHEMBL1200347 |
| ChEBI | CHEBI:6044 |
| EC No. | 200-766-8 |
| DTXSID | DTXSID30221221 |
| 現地名 | ヨウ化イソプロパミド |
化学・物理的性質
| 極性表面積 | 43.1 |
|---|---|
| 水素結合供与体数 | 1 |
| 水素結合受容体数 | 2 |
| 回転可能結合数 | 8 |
| 重原子数 | 27 |
| 形式電荷 | 0 |
| 複雑度 | 419 |
| Human Drugs | FDA approved drugs -> Active ingredient |
| Animal Drugs | FDA approved animal drugs -> Active ingredient |
| Collision Cross Section | 186.9 Ų [M+H]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards] |
| 融点 | 199℃ (Decomposition) |
| 密度 | 1.2711 (estimate) |
| 貯蔵条件 | Store at -20°C |
| 溶解度 | Practically insoluble in waterDMSO: 250 mg/mL (520.37 mM) |
| 外観・状態 | powder to crystal |
| 色 | White to Almost white |
| Merck | 14,5202 |
| 主な用途 | 医薬品（低分子化合物） |
| InChI | 1S/C23H33N2O.HI/c1-18(2)25(5,19(3)4)17-16-23(22(24)26,20-12-8-6-9-13-20)21-14-10-7-11-15-21/h6-15,18-19H,16-17H2,1-5H3,(H2,24,26)1H |
| InChIKey | ZTDSVARXIUOODA-UHFFFAOYSA-N |
| SMILES | I.CC(C)[N](C)(CCC(C(N)=O)(c1ccccc1)c2ccccc2)C(C)C |
安全性と法規制
| GHS 分類 | WarningH315 (98%): Causes skin irritation [Warning Skin corrosion/irritation]P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 51 reports by companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|---|
| 規制情報 | Benzenepropanaminium, .gamma.-(aminocarbonyl)-N-methyl-N,N-bis(1-methylethyl)-.gamma.-phenyl-, iodide: Does not have an individual approval but may be used under an appropriate group standard |
| その他の安全情報 | IMAP assessments - Benzenepropanaminium, .gamma.-(aminocarbonyl)-N-methyl-N,N-bis(1-methylethyl)-.gamma.-phenyl-, iodide: Environment tier I assessment |
| Hazard Classes and Categories | Skin Irrit. 2 (98%) |
| 水環境危害等級（WGK） | 2 |
| RTECS 番号 | BP0693200 |
| 毒性 | LD50 oral in rat: > 10gm/kg |
| 税関コード | 2924296000 |
| 危険文句（R） | 36/37/38 |
| 化審法 | (9)-178 |
| 危険表示 | Xi |
| 安全措置（S） | 26-36 |
| 危険等級 | Eye Irrit. 2Skin Irrit. 2STOT SE 3 |
| 貯蔵分類 | 11 - Combustible Solids |
用途
使用
Isopropamide Iodide acts as an anticholinergic compound with inhibitory activity. Also acts as a muscarinic receptor antagonist which can be applied to treatment of diseases affecting cognition including Alzheimer’s disease.
使用
Isopropamide inhibits muscarinic action of acetylcholine on postganglionic parasympathetic effector regions. It is used for treating stomach ulcers and inflamed intestine.
一般的な説明
Isopropamide iodide, 3-carbamoyl-3,3-diphenylpropyl)diisopropylmethylammoniumiodide (Darbid), occurs as a bitter, white to pale yellow, crystallinepowder that is only sparingly soluble in water butfreely soluble in chloroform and alcohol.This drug, introduced in 1957, is a potent anticholinergic,producing atropine-like effects peripherally. Even with itsquaternary nature, it does not cause sympathetic blockade atthe ganglionic level except at high dosages. Its principal distinguishingfeature is its long duration of action. A singledose can provide antispasmodic and antisecretory effects foras long as 12 hours.